Latest Regulatory Filings News

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

Epsilon Healthcare's December 2023 quarterly report reveals significant boardroom conflict and governance breaches, yet operational segments show promising growth.

Epsilon Healthcare Limited reported a modest cash increase in its December quarter but remains under administration with no unused financing facilities, raising questions about its operational future.

Tombador Iron Limited reported a modest net cash outflow of $317,000 for the December 2024 quarter, yet holds robust cash reserves of $10.825 million, underpinning over 34 quarters of operational funding.

Alchemy Resources Limited reported a slight $15,000 cash outflow in its December 2024 quarter, maintaining a solid cash balance of $2 million as it continues to invest in exploration activities.

Oakridge International Limited reports a strong quarterly performance driven by increased contracted orders, strategic partnerships, and technological innovation, positioning the company for sustained growth into 2025.

True North Copper Limited reported a significant cash outflow in the December 2024 quarter, driven by high operating expenses linked to voluntary administration and exploration activities. Despite ending the quarter with $19.12 million in cash, the company’s negative operating cash flow signals ongoing financial pressure.

Ark Mines Ltd reported a significant cash outflow in its December 2024 quarter, prompting plans for a capital raising to support ongoing exploration activities.

Freehill Mining Ltd’s December quarter cash flow report reveals a $114,000 net cash outflow from operations but highlights a solid liquidity position with $301,000 in unused financing facilities.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Emperor Energy Limited reported a net operating cash outflow of $376,000 for the December quarter but bolstered its cash reserves with a $3.6 million financing inflow, ending the period with $3.4 million in cash.

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.